<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35392704</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1708-8283</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of child neurology</Title>
          <ISOAbbreviation>J Child Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Movement Disorders Secondary to Novel Antiseizure Medications in Pediatric Populations: A Systematic Review and Meta-analysis of Risk.</ArticleTitle>
        <Pagination>
          <StartPage>8830738221089742</StartPage>
          <MedlinePgn>8830738221089742</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/08830738221089742</ELocationID>
        <Abstract>
          <AbstractText>Novel antiseizure medications are thought to be safer than their conventional counterparts, though no dedicated analysis of movement disorder risk among pediatric populations using novel antiseizure medications has been completed. We report a systematic review with meta-analysis describing the relationship between novel antiseizure medications and movement disorders in pediatrics.MEDLINE, EMBASE, and the World Health Organization's International Clinical Trials Registry Platform were searched up to October 2020 for randomized controlled trials investigating novel antiseizure medications in pediatric populations. Antiseizure medications included lacosamide, perampanel, eslicarbazepine, rufinamide, fenfluramine, cannabidiol, and brivaracetam. Outcomes were pooled using random effects models; risk difference (RD) and 95% confidence intervals (CIs) were calculated.Twenty-three studies were selected from 1690 nonredundant manuscripts (n = 1912 total). There was a significantly increased risk of movement disorders associated with perampanel (RD 0.07, 95% CI 0.01-0.13; n = 133), though only 1 relevant trial was found. No increased risk of movement disorders was found with other antiseizure medications.Our findings indicate most novel antiseizure medications are safe to use in pediatric populations with respect to movement disorders. However, findings were limited by quality of adverse event reporting.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Peacock</LastName>
            <ForeName>Dakota J S J</ForeName>
            <Initials>DJSJ</Initials>
            <Identifier Source="ORCID">0000-0001-6135-6551</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Department of Pediatrics, 37210BC Children's Hospital, Vancouver, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoneda</LastName>
            <ForeName>Joshua R K</ForeName>
            <Initials>JRK</Initials>
            <AffiliationInfo>
              <Affiliation>Southern Medical Program, University of British Columbia, Kelowna, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siever</LastName>
            <ForeName>Jodi E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Southern Medical Program, University of British Columbia, Kelowna, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vis-Dunbar</LastName>
            <ForeName>Mathew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Southern Medical Program, University of British Columbia, Kelowna, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boelman</LastName>
            <ForeName>Cyrus</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Department of Pediatrics, 37210BC Children's Hospital, Vancouver, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Child Neurol</MedlineTA>
        <NlmUniqueID>8606714</NlmUniqueID>
        <ISSNLinking>0883-0738</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antiseizure medications</Keyword>
        <Keyword MajorTopicYN="N">ataxia</Keyword>
        <Keyword MajorTopicYN="N">children</Keyword>
        <Keyword MajorTopicYN="N">epilepsy</Keyword>
        <Keyword MajorTopicYN="N">outcome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35392704</ArticleId>
        <ArticleId IdType="doi">10.1177/08830738221089742</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
